Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of ofatumumab combined with ESHAP as salvage therapy before autologous stem cell transplantation in relapsed or refractory diffuse large B cell lymphoma
2012-000933-37Phase 2Completed
- Sponsor
- National and Kapodistrian University of Athens
- Start
- Aug 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ofatumumab in diffuse large B-cell lymphoma (DLBCL), sponsored by National and Kapodistrian University of Athens. Primary endpoint: overall response rate. Started Aug 2012; status: completed.
02
Drugs
ofatumumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2012-000933-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000933-37.